Personalis Inc. (NASDAQ: PSNL) presented clinical data on its NeXT Personal ctDNA monitoring technology at the American Association for Cancer Research Annual Meeting. The presentation included one oral presentation and three posters demonstrating the technology's applications in treatment monitoring and resistance tracking.

The NEOPRISM-CRC trial, presented by Dr. Jiang from University College London, used NeXT Personal to monitor patients with high-risk stage II-III colorectal cancer receiving neoadjuvant pembrolizumab. The study identified three patient response groups: super molecular responders who cleared ctDNA by the second treatment cycle achieved 100% pathological complete response, while poor molecular responders with stable ctDNA levels achieved 0% pathological complete response. The test demonstrated 100% sensitivity for disease at baseline and 100% negative predictive value post-surgery.

In a real-world analysis of nearly 25,000 plasma samples from 10,000 patients, NeXT Personal showed a median limit of detection of 1.92 PPM. The study found that 39% of positive minimal residual disease detections occurred below 100 PPM, with 14.6% below 10 PPM. The analysis covered more than 14 cancer types and stage I-IV disease.

Personalis introduced Real-Time Variant Tracker, a new feature for simultaneously monitoring minimal residual disease and tracking resistance-associated mutations. With specificity exceeding 99.9%, resistance mutations were identified in 38% of MRD-positive patients in the real-world cohort.

The DARWIN 2 study in metastatic non-small cell lung cancer showed patients achieving durable molecular complete response remained 100% progression-free at three years, while those without molecular clearance were five times more likely to experience disease progression.

"The data presented at AACR confirm ultrasensitive ctDNA detection with NeXT Personal as a promising therapy monitoring tool in neoadjuvant colorectal cancer treatment," said Dr. Richard Chen, President and Chief Medical Officer at Personalis.